ORIGINAL ARTICLE

Neuromyelitis optica: Association with paroxysmal painful tonic spasms


* Consultorio de Neuroinmunología, Servicio de Neurología, Hospital General de Agudos Dr. Carlos G. Durand, Buenos Aires, Argentina
b Servicio de Neurología, Hospital General de Agudos Dr. Teodoro Álvarez, Buenos Aires, Argentina

Received 3 June 2014; accepted 2 December 2014
Available online 29 August 2016

Abstract
Introduction: Paroxysmal painful tonic spasms (PPTS) were initially described in multiple sclerosis (MS) but they are more frequent in neuromyelitis optica (NMO). The objective is to report their presence in a series of cases of NMO and NMO spectrum disorders (NMOSD), as well as to determine their frequency and clinical features.
Patients and methods: We conducted a retrospective assessment of medical histories of NMO/NMOSD patients treated in 2 hospitals in Buenos Aires (Hospital Durand and Hospital Álvarez) between 2009 and 2013.
Results: Out of 15 patients with NMOSD (7 with definite NMO and 8 with limited NMO), 4 presented PPTS (26.66%). PPTS frequency in the definite NMO group was 57.14% (4/7). Of the 9 patients with longitudinally extensive transverse myelitis (LETM), 44.44% (9/15) presented PPTS. Mean age was 35 years (range, 22-38 years) and all patients were women. Mean time between NMO diagnosis and PPTS onset was 7 months (range, 1-29 months) and mean time from last relapse of LETM was 30 days (range 23-40 days). LETM (75% cervicothoracic and 25% thoracic) was observed by magnetic resonance imaging (MRI) in all patients. Control over spasms and pain was achieved in all patients with carbamazepine (associated with gabapentin in one case). No favourable responses to pregabalin, gabapentin, or phenytoin were reported.
Conclusions: PPTS are frequent in NMO. Mean time of PPTS onset is approximately one month after an LETM relapse, with extensive cervicothoracic lesions appearing on the MRI scan. They show an excellent response to carbamazepine but little or no response to pregabalin and gabapentin. Prospective studies with larger numbers of patients are necessary in order to confirm these results.

© 2014 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.


* Corresponding author.
E-mail address: junior.carnero@hotmail.com (E. Carnero Contentti).
Introduction

Paroxysmal painful tonic spasms (PPTS) are stereotypical, recurrent, localised muscle spasms (in one or more limbs and/or the trunk) lasting around 20 to 45 seconds and accompanied by intense pain and dystonia. Episodes may or may not be triggered by sudden movements or sensory stimuli and can be classified as either cerebral or spinal depending on the location of the lesion. Due to their negative impact on quality of life, rehabilitation, and daily living activities, PPTS should be suspected, diagnosed, and treated as soon as possible.

Although PPTS were first described by Matthews in patients with multiple sclerosis (MS) in 1958, recently published studies suggest that they are more frequent in neuromyelitis optica (NMO), with an incidence ranging between 3% and 35% in patients with demyelinating myelopathy of different causes (MS, NMO, idiopathic).

We analysed a series of patients who met the diagnostic criteria for NMO/neuromyelitis optica spectrum disorder (NMOSD) in order to determine clinical characteristics, response to treatment, and frequency of association of PPTS with NMO and NMOSD.

Materials and methods

We retrospectively reviewed the medical histories of all patients attending the neurology department at 2 centres in Buenos Aires (Hospital General de Agudos Dr. Carlos G. Durand and Hospital General de Agudos Dr. Teodoro Álvarez) between January 2009 and December 2013.

We included all patients with defined NMO or NMOSD with anti-aquaporin-4 (AQP4) antibodies. We used the Wingerchuk et al. 2006 diagnostic criteria for NMO: (1) acute transverse myelitis (ATM) plus optic neuritis (ON) and (2) at least 2 of the following features: MRI findings that are normal or non-diagnostic for MS according to Barkhof and Tintore’s criteria, MRI scan showing involvement of at least 3 spinal cord segments (longitudinally extensive transverse myelitis [LETM]), and serum positivity for NMO-IgG or AQP4 antibodies. Following the Wingerchuk et al. 2007 diagnostic criteria, NMOSD included the limited forms of NMO (recurrent or simultaneous bilateral ON, single or recurrent events of LETM), optic-spinal MS, ON or LETM associated with systemic autoimmune disease, and ON or myelitis associated with brain lesions typical of NMO. Likewise, PPTS was defined as previously stated.

Results

We found 15 patients with NMO/NMOSD, of whom 7 had defined NMO and 8 had limited NMOSD. Three of the 8 patients with NMOSD had recurrent ON, 3 had isolated ON, and 2 had isolated LETM. Four patients in our sample had PPTS (26.66%). PPTS were detected in 57.14% (4/7) of the patients with defined NMO and none of the patients with NMOSD (0/8). Likewise, PPTS were seen in 44.44% of all patients with LETM (4/9).

None of the patients had experienced cervicothoracic or head trauma, had a family or personal history of dystonia, or were taking anti-dopaminergic drugs (for example, neuroleptics). We will now describe the 4 reported cases of PPTS (Table 1).
### Table 1

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age/years</th>
<th>Start of neurological symptoms</th>
<th>MRI spinal cord segments</th>
<th>MRI brain MRI</th>
<th>MRI PPTS (affected limbs)</th>
<th>Time from ATM to PPTS onset (days)</th>
<th>Time since diagnosis of NMO (months)</th>
<th>Treatment</th>
<th>Satisfactory response/ adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>44</td>
<td>Patient 1</td>
<td>C1-T2</td>
<td>Normal</td>
<td>LETM</td>
<td>30</td>
<td>9</td>
<td>Carbamazepine 600 mg, Gabapentin 1200 mg</td>
<td>No response/adverse effects</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>Patient 2</td>
<td>C1-T1</td>
<td>UL and LL</td>
<td>PPTS (affected limbs)</td>
<td>40</td>
<td>1/10</td>
<td>Phenytoin (AE), Carbamazepine 400 mg</td>
<td>Satisfactory response</td>
</tr>
<tr>
<td>F</td>
<td>34</td>
<td>Patient 3</td>
<td>C1-T10</td>
<td>UL and LL</td>
<td>Left ON</td>
<td>29</td>
<td>5</td>
<td>Carbamazepine 1200 mg, gabapentin 400 mg</td>
<td>No response/adverse effects</td>
</tr>
<tr>
<td></td>
<td>37</td>
<td>Patient 4</td>
<td>C2-T2</td>
<td>rUL</td>
<td>Right ON</td>
<td>32</td>
<td>5</td>
<td>Carbamazepine 1200 mg, Gabapentin 400 mg</td>
<td>No response/adverse effects</td>
</tr>
</tbody>
</table>

**Patient 1**

Our first patient was a 44-year-old woman with LETM and bilateral ON who was treated with IV methylprednisolone and oral corticosteroids. Treatment led to partial improvement of symptoms. However, 9 months later she experienced a relapse with severe quadriparesis and extensive cervical spinal cord lesions. Treatment with corticosteroids, azathioprine, and plasmapheresis improved her symptoms. A month later she experienced PPTS in all limbs. Although her condition improved rapidly with phenytoin, treatment had to be discontinued due to hepatotoxicity. She responded poorly to pregabalin and gabapentin. Her condition improved with carbamazepine dosed at 600 mg/day but treatment was discontinued due to an increase in transaminases. She has improved slowly over the past months.

**Patient 2**

The second patient was a 22-year-old woman with a 4-year history of left ON who experienced thoracic LETM. She improved with IV methylprednisolone, oral corticosteroids, and azathioprine. Forty days later, she presented progressive PPTS in the lower limbs. She showed no response to pregabalin and was subsequently treated with phenytoin with excellent results. However, treatment had to be discontinued due to a skin reaction. She showed no response to gabapentin. Carbamazepine 1200 mg/day led to substantial improvements.

**Patient 3**

The third patient was a 34-year-old woman with a 29-month history of right ON who developed left ON 8 months after onset of right ON. She developed cervicothoracic LETM associated with sensory alterations in the upper limbs and paraparesis in the lower limbs. She improved with IV methylprednisolone, oral corticosteroids, and azathioprine. Twenty-three days later she developed PPTS in both upper limbs and the right lower limb. She showed no response to pregabalin but improved significantly with carbamazepine 400 mg/day.

**Patient 4**

Our fourth patient was a 37-year-old woman with a 5-month history of right ON who also developed cervicothoracic LETM. Treatment with IV methylprednisolone, oral corticosteroids, and azathioprine improved her symptoms. Thirty days later, she developed PPTS in the right upper limb. In addition to gabapentin, which delivered little relief, she was also treated with carbamazepine 1200 mg/day, leading to substantial improvements.

In summary, mean age in our patient sample (n = 4) was 35 years (range, 22-38 years). All patients were women. Mean time elapsed from diagnosis of NMO to onset of spasms was 7 months (range, 1-29 months); mean time from the last LETM relapse was 30 days (range, 23-40 days). MRI studies showed all patients to have LETM (cervicothoracic in 75% and thoracic in 25%). Our patients developed PPTS
a mean of 7 months after diagnosis (range, 1-29 months) and a mean of 30 days after an LETM relapse (range, 23-40 days). PPTS occurred after the first episode of LETM in 3 patients and after the second episode in the remaining one (patient 1). Seventy-five percent of the patients were treated with gabapentin with no response; 50% did not respond to pregabalin. Half of the patients received phenytoin and while response was good, they had to discontinue treatment due to adverse effects (skin reaction and hepatotoxicity). Carbamazepine successfully managed PPTS and pain in all patients (in association with gabapentin in one case). They all received acute treatment with IV methylprednisolone and were administered azathioprine plus oral meprednisone to prevent relapses.

**Discussion**

In our study, 4 of the 15 patients with NMO/NMOSD experienced PPTS (26.66%); this percentage increases if we consider only the patients with LETM (44.44%) and it is even greater among patients with defined NMO (57.14%). In contrast, according to recent literature, fewer than 5% of the patients with MS develop PPTS. Studies of MS conducted in Western countries report similar figures (2%-10%). However, a study conducted in Japan revealed a higher incidence (17.18%) in patients with MS. These data may be misleading since a high percentage of these patients showed extensive spinal cord demyelination which might therefore correspond to optic-spinal MS, an entity which some authors include within NMOSD. These data suggest that PPTS are more frequent in NMO than in MS. In addition, a study found that pain is more severe and debilitating in patients with NMO than in those with MS. This may be explained by the fact that NMO, unlike MS, frequently causes transverse myelitis with severe demyelination and tissue necrosis (spinal cord) since anti-AQP4 antibodies, which belong to the IgG1 isotype, induce complement-dependent cytotoxicity. Likewise, cytokines (including IL-17, IL-8, and granulocyte colony stimulating factor) recruit neutrophils and eosinophils into perivascular spaces, where neutrophils degranulate and cause astrocyte death. Astrocyte loss leads to oligodendrocyte death, which in turn provokes axonal degeneration and neuronal death.

It should be noted that none of our patients experienced PPTS at the onset of NMO. At disease onset, one exhibited ON associated with LETM (patient 1) whereas the remaining patients had ON exclusively. PPTS were associated with LETM relapses, occurring a mean of 30 days after the episode.

**Table 2** Comparison of clinical, demographic, and treatment characteristics of 2 case series including NMO patients with PPTS and our own.

<table>
<thead>
<tr>
<th>Clinical, demographic, and treatment characteristics</th>
<th>Kim et al.</th>
<th>Usmani et al.</th>
<th>Carnero Contentti et al.</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis of defined/limited NMOSD (n)</td>
<td>40</td>
<td>57</td>
<td>15</td>
<td>112</td>
</tr>
<tr>
<td>Diagnosis of PPTS (n)</td>
<td>10</td>
<td>8</td>
<td>4</td>
<td>22</td>
</tr>
<tr>
<td>Incidence of PPTS in NMO (%)</td>
<td>25</td>
<td>14</td>
<td>26</td>
<td>49.46</td>
</tr>
<tr>
<td>Sex (women/men)</td>
<td>10/0</td>
<td>7/1</td>
<td>4/0</td>
<td>21/1</td>
</tr>
<tr>
<td>Mean age at diagnosis of NMOSD (years)</td>
<td>48.3</td>
<td>39.5</td>
<td>32</td>
<td>39.9</td>
</tr>
<tr>
<td>Mean time from diagnosis of NMO to PPTS (months)</td>
<td>240</td>
<td>24.6</td>
<td>7</td>
<td>90.53</td>
</tr>
<tr>
<td>Incidence of PPTS after LETM (%)</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Mean time from last LETM relapse (days)</td>
<td>80**</td>
<td>48.13</td>
<td>30</td>
<td>52.6</td>
</tr>
<tr>
<td>Mean number of affected spinal segments</td>
<td>5.3</td>
<td>10.25</td>
<td>12.5</td>
<td>9.35</td>
</tr>
<tr>
<td>Patients with cervical involvement (n)</td>
<td>4</td>
<td>NR</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Patients with cervicothoracic involvement (n)</td>
<td>5</td>
<td>NR</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Patients with thoracic involvement (n)</td>
<td>1</td>
<td>NR</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Affected limbs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UL: rUL, rUL, bUL</td>
<td>2/1/1</td>
<td>3/2/0</td>
<td>0/0/1</td>
<td>4/3/2</td>
</tr>
<tr>
<td>LL: rLL, rLL, bLL</td>
<td>0/1/3</td>
<td>1/3/0</td>
<td>1/0/1</td>
<td>3/4/4</td>
</tr>
<tr>
<td>All 4 limbs</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Treatment with carbamazepine (n, %)</td>
<td>4 (40)***</td>
<td>8 (100)</td>
<td>4 (100)</td>
<td>16 (73)</td>
</tr>
<tr>
<td>Response to carbamazepine (n, %)</td>
<td>4 (100)***</td>
<td>8 (100)</td>
<td>4 (100)</td>
<td>16 (100)</td>
</tr>
</tbody>
</table>

bUL: both lower limbs; bUL: both upper limbs; PPTS: paroxysmal painful tonic spasms; LETM: longitudinally extensive transverse myelitis; rLL: right lower limb; rUL: left upper limb; rUL: right upper limb; IL: left upper limb; n: number; NMOSD: neuromyelitis optica spectrum disorder; NR: not reported.

a One patient presented PPTS and NMO simultaneously: patient 2 experienced PPTS 4490 days after diagnosis of NMO, and patient 4, 1963 days after diagnosis of NMO. For this reason, the mean time from diagnosis of NMO to PPTS was 240 months. If we excluded the outliers, the mean time would be 25.5 months (80% of the sample).

**90%** of the episodes of PPTS occurred within the first 80 days after the first episode of myelitis. PPTS occurred a mean of 48.13 days after the first episode of LETM (8 out of 10 patients, 80%).

***40%*** of the patients were treated with phenytoin (10% of these in combination with carbamazepine), 20% with gabapentin, and 10% with baclofen and showed good response.

* Patient 1 showed PPTS on the left side of the body (bUL + lLL), and patient 4 on the right side of the body (rUL + rLL); they have therefore been included in 2 categories of limb involvement.

b Patient 3 showed PPTS on bUL and the rLL; she has therefore been included in 2 categories of limb involvement.
In a recent study, PPTS were found to be associated with recovery from the first episode of myelitis, suggesting that partial remyelination of the spinal cord plays a major role in PPTS pathogenesis compared to demyelination caused by NMO. According to another recent study, presence of PPTS after the first episode of ATM is a criterion with 100% specificity and 67% sensitivity for NMO. These results suggest that occurrence of PPTS may be included in the diagnostic criteria for NMO.

The pathophysiology of PPTS in NMO is yet to be fully understood. However, a study by Ostermann and Westerberg on MS and PPTS proposed that chemical mediators of inflammation (arachidonic acid, leucotrienes, and prostaglandins) lead to axonal irritation, causing PPTS. In another study, these authors suggested that early impairment of afferent fibres in the spinal cord while corticospinal fibres remain relatively intact would activate ephaptic transmission, leading to axonal diffusion within a partially demyelinated lesion in fibre tracts. Since PPTS are frequently bilateral, one hypothesis is that they are caused by lesions at the level of the medulla oblongata (pyramidal decussation), the spinal cord, or both. In our sample, 3 patients (patients 1, 3, and 4) exhibited high cervical lesions; 2 of these patients (1 and 3) showed bilateral PPTS. However, PPTS were also observed in a patient with lesions in the thoracic spinal cord (patient 2). Further studies including larger sample sizes should be conducted to confirm this hypothesis.

Regarding treatment, all 4 patients showed an excellent response to carbamazepine. Two patients responded well to phenytoin but experienced adverse effects and had to discontinue treatment. Gabapentin and pregabalin had no beneficial effects in our patient sample. These results agree with those of most published studies; however, controlled clinical trials should be conducted to confirm our findings.

The limitations of our study include its small sample size and its retrospective design. Our results should therefore be confirmed by prospective studies with larger numbers of patients. It should be noted that few published studies (most of which are case series) have specifically addressed the association between NMO and PPTS and reported similar results to our own (Table 2). This observation led us to publish this study despite its small sample size.

Conclusions

PPTS are frequent in patients with NMO (57.14% in our series). Although first described in MS, they are less common in this disease than in NMO (<10%). In our sample, none of the patients with NMOSD showed this association since these patients mainly had ON (either isolated or recurrent). PPTS generally appear a month after a myelitis relapse and are associated with extensive cervicothoracic lesions in MRI. They should not be regarded as a manifestation of disease relapse but rather as a paroxysmal symptom that should be recognised and treated to minimise their impact on patients’ quality of life. Pregabalin and gabapentin have little to no effect on PPTS whereas carbamazepine achieves excellent results and should therefore be considered the treatment of choice.

Conflicts of interest

The authors have no conflicts of interest to declare.

References